TCI Wealth Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

TCI Wealth Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-126	Closed	-$13.5K	–	2483
2023 Q1	$13.5K	Buy	126 +61	+94%	+$7.02K	﹤0.01%	905
2022 Q4	$7.15K	Buy	+65	New	+$4.21K	﹤0.01%	1294
2022 Q2	–	Sell	-133	Closed	-$5K	–	2597
2022 Q1	$5K	Buy	+133	New	+$5.26K	﹤0.01%	1637

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

TCI Wealth Advisors's RXDX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 126 shares — an estimated $13.5K sold.

TCI Wealth Advisors first reported a position in RXDX in Q1 2022 and held it in 3 quarters. The position peaked at $13.5K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

TCI Wealth Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 126 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $13.5K.
TCI Wealth Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
TCI Wealth Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $13.5K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.